- Home
- AGI vs VTRS Comparison
AGI vs VTRS Comparison
Compare AGI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGI
- VTRS
- Stock Information
- Founded
- AGI 1993
- VTRS 1961
- Country
- AGI Philippines
- VTRS United States
- Employees
- AGI N/A
- VTRS N/A
- Industry
- AGI Precious Metals
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- AGI Basic Materials
- VTRS Health Care
- Exchange
- AGI Nasdaq
- VTRS Nasdaq
- Market Cap
- AGI 11.2B
- VTRS 11.0B
- IPO Year
- AGI 1999
- VTRS N/A
- Fundamental
- Price
- AGI $24.84
- VTRS $8.81
- Analyst Decision
- AGI Buy
- VTRS Hold
- Analyst Count
- AGI 4
- VTRS 5
- Target Price
- AGI $30.38
- VTRS $10.40
- AVG Volume (30 Days)
- AGI 3.6M
- VTRS 7.5M
- Earning Date
- AGI 07-30-2025
- VTRS 08-07-2025
- Dividend Yield
- AGI 0.01%
- VTRS 5.45%
- EPS Growth
- AGI 57.62
- VTRS N/A
- EPS
- AGI 0.82
- VTRS N/A
- Revenue
- AGI $1,507,900,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- AGI N/A
- VTRS N/A
- Revenue Next Year
- AGI $17.45
- VTRS $1.85
- P/E Ratio
- AGI $30.45
- VTRS N/A
- Revenue Growth
- AGI 29.86
- VTRS N/A
- 52 Week Low
- AGI $15.74
- VTRS $6.85
- 52 Week High
- AGI $31.00
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- AGI 41.93
- VTRS 42.87
- Support Level
- AGI $23.92
- VTRS $8.84
- Resistance Level
- AGI $26.19
- VTRS $9.27
- Average True Range (ATR)
- AGI 0.79
- VTRS 0.24
- MACD
- AGI -0.13
- VTRS -0.06
- Stochastic Oscillator
- AGI 32.62
- VTRS 22.70
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has four operating segments being Young-Davidson, Island Gold and Magino mines operate in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Mulatos mines.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.